45.03

3.16% 1.42

Legend Biotech Corp Adr (LEGN)

Overview News Price History Option Chain Why LEGN Down? Discussions Forecast

Legend Biotech Corp Adr stock is traded at $45.03, with a volume of 2.03M. It is up +3.16% in the last 24 hours and down -8.32% over the past month. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Previous Close:

$43.61

Open:

$45

24h Volume:

2.03M

Relative Volume:

2.15

Market Cap:

$8.68B

Revenue:

$455.99M

Net Income/Loss:

$-285.01M

P/E Ratio:

-13.81

EPS:

-3.26

Net Cash Flow:

$-164.61M

1W Performance:

-1.04%

1M Performance:

-8.32%

6M Performance:

-0.93%

1Y Performance:

-31.81%

1-Day Range:

$44.87

$47.79

1-Week Range:

$42.84

$47.79

52-Week Range:

$38.60

$70.13

Legend Biotech Corp Adr Stock (LEGN) Company Profile

Name

Legend Biotech Corp Adr

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

Address

Employee

1,800

Twitter

@LegendBiotech

Next Earnings Date

2024-11-12

Latest SEC Filings

LEGN's Discussions on Twitter

Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Initiated	Scotiabank	Sector Perform
Nov-06-23	Initiated	Goldman	Buy
May-25-23	Initiated	William Blair	Mkt Perform
May-22-23	Initiated	Daiwa Securities	Buy
Mar-29-23	Initiated	H.C. Wainwright	Buy
Mar-24-23	Initiated	RBC Capital Mkts	Outperform
Dec-06-22	Initiated	UBS	Buy
Nov-02-22	Initiated	Evercore ISI	Outperform
Nov-01-22	Initiated	Cowen	Outperform
Oct-31-22	Initiated	Guggenheim	Neutral
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Mar-15-22	Initiated	Barclays	Overweight
Jan-31-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-21-21	Initiated	Piper Sandler	Overweight
May-18-21	Initiated	BTIG Research	Buy
Jul-01-20	Initiated	JP Morgan	Overweight
Jul-01-20	Initiated	Jefferies	Buy
Jun-30-20	Initiated	Morgan Stanley	Overweight

View All

Legend Biotech Corp Adr Stock (LEGN) Latest News

02:42 AM

Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com

02:42 AM

Nov 04, 2024

Gilead Science to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research

Nov 04, 2024

Legend Biotech appoints new President for CARVYKTI - Investing.com

Nov 04, 2024

Oct 28, 2024

Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register

Oct 28, 2024

Oct 24, 2024

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance

Oct 24, 2024

Oct 17, 2024

Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register

Oct 17, 2024

Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India

Oct 17, 2024

Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India

Oct 17, 2024

Oct 16, 2024

Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 16, 2024

Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily

Oct 16, 2024

Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily

Oct 16, 2024

Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily

Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales - Investing.com

Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 15, 2024

Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex

Oct 15, 2024

Legend Biotech Corp ADR’s results are impressive - US Post News

Oct 15, 2024

UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers - Investing.com

Oct 15, 2024

Oct 11, 2024

Legend Biotech maintains shares price target on steady Q3 growth - Investing.com

Oct 11, 2024

Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle

Oct 11, 2024

Oct 10, 2024

Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex

Oct 10, 2024

Oct 09, 2024

Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com

Oct 09, 2024

Oct 08, 2024